UnknownNot Applicable

Efficacy and Safety of Endoscopic Papillectomy in the Treatment of Ampullary Neoplasms.

Italy400 participantsStarted 2022-04-01

Plain-language summary

The aim of our study is to provide data on the efficacy and safety of endoscopic papillectomy, by including consecutive patients treated after 2015, when first guidelines on endoscopic management of ampullary neoplasms were available.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Ampullary neoplasm, confirmed by histological examination of the endoscopically resected specimen Exclusion Criteria: * Absence of dysplasia on the resected specimen; * Locally advanced or metastatic disease (Clinical TNM stage \>T1 or N+ or M+); * Neoplasm Intra-Ductal Extension (IDE) \> 20 mm; * Previously treated ampullary neoplasm.

What they're measuring

Clinical Success

Timeframe: 2016-2021

Trial details

NCT IDNCT05690412

SponsorAzienda Unità Sanitaria Locale della Romagna

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-03-31

Contact for this trial

Carlo Fabbri, MD

3389353104 carlo.fabbri@auslromagna.it

View on ClinicalTrials.gov More Ampullary Adenoma trials